Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments
Key takeaways
- Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments Sheryar Siddiq Tue, June 2, 2026 at 4:37 PM GMT+7 1 min read SMMT Summit Therapeutics Inc.
- The trial failed to meet an interim progression-free survival threshold, increasing investor doubts regarding its efficacy in comparison to data from HARMONi-6, a China-exclusive trial.
- Cantor Fitzgerald reported that medical professionals were less deterred by the interim progression-free survival shortfall.
Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments Sheryar Siddiq Tue, June 2, 2026 at 4:37 PM GMT+7 1 min read SMMT Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best short squeeze stocks to invest in. On May 22, Cantor Fitzgerald restated its Overweight rating for Summit Therapeutics Inc. (NASDAQ:SMMT). The firm addressed concerns about the HARMONi-3 trial, which is evaluating ivonescimab in first-line squamous non-small cell lung cancer.
The trial failed to meet an interim progression-free survival threshold, increasing investor doubts regarding its efficacy in comparison to data from HARMONi-6, a China-exclusive trial.
Cantor Fitzgerald reported that medical professionals were less deterred by the interim progression-free survival shortfall. The expert opinion was influenced by the firm’s low alpha spend and the fact that the analysis was performed very early.